{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:36:39Z","timestamp":1793835399318,"version":"4.6.1"},"reference-count":259,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,7,24]]},"DOI":"10.1080\/14656566.2026.2702380","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:47:24Z","timestamp":1784818044000},"page":"1125-1148","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Recent advances in EGFR-targeted therapies for non-small cell lung cancer"],"prefix":"10.1080","volume":"27","author":[{"given":"Luca","family":"Lucente","sequence":"first","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Barcellini","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Ramella Pollone","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Lidia","family":"Filipazzi","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Coco","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Puppo","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Marconi","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Santamaria","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tagliamento","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Rossi","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Dellepiane","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bennicelli","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Barletta","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Zinoli","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-8582","authenticated-orcid":false,"given":"Carlo","family":"Genova","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_5_5_1","unstructured":"Cancer Today [Internet]. [cited 2026 Jan 31]. Available from: https:\/\/gco.iarc.who.int\/today\/en"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00798-3"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00844-0"},{"key":"e_1_3_5_8_1","unstructured":"Cancer Prevention & Early Detection | American Cancer Society [Internet]. [cited 2026 Feb 1]. Available from: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/cancer-prevention-early-detection.html"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.12.655"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09219-0"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.05.14"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01691"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2925"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.3224"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00312-3"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010383.pub3"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015140.pub2"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1609"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/35052073"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.7.4188"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/4.2.86"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/309418a0"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1006\/geno.2000.6341"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00963-7"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01392"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4827(02)00105-2"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2466334"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.13.7495"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2010.04.008"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904554"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"issue":"9","key":"e_1_3_5_33_1","first-page":"2702s","article-title":"Chromosome abnormalities in human non-small cell lung cancer","volume":"52","author":"Testa JR","year":"1992","unstructured":"Testa JR, Siegfried JM. Chromosome abnormalities in human non-small cell lung cancer. Cancer Res. 1992;52(9 Suppl):2702s\u20132706s.","journal-title":"Cancer Res"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9050052"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60765-4"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0103"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.14409"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12055"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207115"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.06.009"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70295"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101364"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00248-4"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.181181198"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1101-973"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes12071094"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-141"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00287"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6020708"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/21623996.2014.999503"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1181"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5112"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.828673"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.575464"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.016"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0579-CP"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00971-2"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3497"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2266"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030629"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.01.020"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70604-1"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71173-8"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30033-X"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30608-3"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S119644"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.598265"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510308"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102588"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT017"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403614"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503001"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2025.2467338"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.541"},{"key":"e_1_3_5_80_1","unstructured":"Study details | NCT04695925 | osimertinib monotherapy or combination with chemotherapy for advanced NSCLC concurrent EGFR and TP53 mutations | ClinicalTrials.Gov [Internet]. [cited 2026 Apr 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04695925?tab=study"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106309"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.01.018"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.07.117"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.09.015"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12996"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2088"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1159\/000484175"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12587"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.10.012"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-025-03774-y"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03898-1"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2026.103948"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00026-1"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02007"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103592"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5013"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00931"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02835"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.8501"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115917"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.03.016"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61817-8"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2072"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01269"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00662"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306441"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217904"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00763"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.1449"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8668"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2358"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2604461"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2457294"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.033"},{"key":"e_1_3_5_115_1","unstructured":"Study details | NCT05607550 | study to compare furmonertinib to platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (FURVENT) | ClinicalTrials.gov [Internet]. [cited 2026 Apr 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05607550"},{"key":"e_1_3_5_116_1","unstructured":"Study details | NCT05767892 | YK-029A as first-line treatment versus platinum-based chemotherapy for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations | ClinicalTrials.gov [Internet]. [cited 2026 Apr 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05767892"},{"key":"e_1_3_5_117_1","unstructured":"Study details | NCT06380348 | JMT101 in combination with osimertinib versus cisplatin-pemetrexed in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by epithermal growth factor receptor (EGFR) exon 20ins mutations | ClinicalTrials.gov [Internet]. [cited 2026 Apr 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06380348"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39139-4"},{"key":"e_1_3_5_119_1","unstructured":"Study details | NCT05132777 | efficacy and safety of JMT101 combined with osimertinib in patients with non-small cell lung cancer | ClinicalTrials.gov [Internet]. [cited 2026 Apr 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05132777"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106314"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107528"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010236"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.03.009"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01085-z"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100051"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0709662105"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx703"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2246"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-014-0344-7"},{"issue":"7","key":"e_1_3_5_130_1","first-page":"2513","article-title":"Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma","volume":"30","author":"Uramoto H","year":"2010","unstructured":"Uramoto H, Iwata T, Onitsuka T, et al. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res. 2010;30(7):2513\u20132517.","journal-title":"Anticancer Res"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002003"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2100"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35962-x"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713077"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67950-8"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1022"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00557-2"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.11.009"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3563"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.06.002"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8565"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3990"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00191"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01425-5"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.11.022"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35961-y"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3829"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.056"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105807"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.184"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2297"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.117"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2025.12.005"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000003003"},{"key":"e_1_3_5_157_1","unstructured":"Rybrevant | European Medicines Agency (EMA) [Internet]. [cited 2026 Mar 10]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rybrevant"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00064-0"},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00297"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e20515"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00012-9"},{"key":"e_1_3_5_163_1","unstructured":"Study details | NCT04311034 | a study of RC48-ADC in subjects with advanced non-small cell lung cancer | ClinicalTrials.gov [Internet]. [cited 2026 Mar 8]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04311034"},{"key":"e_1_3_5_164_1","unstructured":"Study details | NCT06430437 | a study of SHR-A1811 in first-line treatment of patients with advanced or metastatic non-small cell lung cancer with HER2 mutations | ClinicalTrials.gov [Internet]. [cited 2026 Mar 8]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06430437"},{"key":"e_1_3_5_165_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0306"},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2693"},{"key":"e_1_3_5_167_1","unstructured":"Study details | NCT04886804 | beamion LUNG-1: a study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene) | ClinicalTrials.gov [Internet]. [cited 2026 Mar 8]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04886804"},{"key":"e_1_3_5_168_1","unstructured":"Study details | NCT05099172 | first in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epidermal growth factor receptor (EGFR) and\/or human epidermal growth factor receptor 2 (HER2) | ClinicalTrials.gov [Internet]. [cited 2026 Mar 8]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05099172"},{"key":"e_1_3_5_169_1","unstructured":"Study details | NCT03944772 | phase 2 platform study in patients with advanced non-small lung cancer who progressed on first-line osimertinib therapy (ORCHARD) | ClinicalTrials.gov [Internet]. [cited 2026 Apr 8]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03944772"},{"key":"e_1_3_5_170_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9156"},{"key":"e_1_3_5_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.04.003"},{"key":"e_1_3_5_172_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01476"},{"key":"e_1_3_5_173_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0602"},{"key":"e_1_3_5_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00270-5"},{"key":"e_1_3_5_175_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8507"},{"key":"e_1_3_5_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.085"},{"key":"e_1_3_5_177_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613"},{"key":"e_1_3_5_178_1","unstructured":"Study details | NCT04816214 | study evaluating efficacy and safety of Capmatinib in combination with osimertinib in adult subjects with non-small cell lung cancers as second line therapy | ClinicalTrials.Gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04816214"},{"key":"e_1_3_5_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01811-2"},{"key":"e_1_3_5_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.002"},{"key":"e_1_3_5_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100886"},{"key":"e_1_3_5_182_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.086"},{"key":"e_1_3_5_183_1","unstructured":"Gandhi S Chang E Antonoff MB et al. Predictors of benefit from local consolidative therapy and patterns of failure for metastatic EGFR-mutant NSCLC: a secondary analysis of NorthStar a phase II randomized clinical trial. p. 1\u201397. Available from: https:\/\/oncologypro.esmo.org\/congress-resources\/european-lung-cancer-congress-2026?presentation=predictors_of_benefit_from_local_consolidative_the_b0b2944"},{"key":"e_1_3_5_184_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231225036"},{"key":"e_1_3_5_185_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01017"},{"key":"e_1_3_5_186_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02747"},{"key":"e_1_3_5_187_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30084-0"},{"key":"e_1_3_5_188_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00382-5"},{"key":"e_1_3_5_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.10.014"},{"key":"e_1_3_5_190_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106322"},{"key":"e_1_3_5_191_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01891"},{"key":"e_1_3_5_192_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7"},{"key":"e_1_3_5_193_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43046-025-00264-4"},{"key":"e_1_3_5_194_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4052"},{"key":"e_1_3_5_195_1","doi-asserted-by":"publisher","DOI":"10.1177\/11795549241260534"},{"key":"e_1_3_5_196_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01349"},{"key":"e_1_3_5_197_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01544"},{"key":"e_1_3_5_198_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251385410"},{"key":"e_1_3_5_199_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(25)00196-0"},{"key":"e_1_3_5_200_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ-2025-085680"},{"key":"e_1_3_5_201_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106960"},{"key":"e_1_3_5_202_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512071"},{"key":"e_1_3_5_203_1","unstructured":"Study details | NCT06305754 | Sacituzumab tirumotecan (MK-2870) versus pemetrexed and carboplatin combination therapy in participants with epidermal growth factor (EGFR)-mutated advanced nonsquamous non-small cell lung cancer (NSCLC) who have progressed on prior EGFR tyrosine kinase inhibitors (MK-2870\u2013009) | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06305754"},{"key":"e_1_3_5_204_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.003"},{"key":"e_1_3_5_205_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3359"},{"key":"e_1_3_5_206_1","unstructured":"HERTHENA-Lung01: a phase 2 randomized open-label study of patritumab deruxtecan (U3-1402) in subjects with previously treated metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC) [Internet]. 2020 [cited 2021 Feb 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04619004"},{"key":"e_1_3_5_207_1","unstructured":"Study details | NCT05338970 | HERTHENA-Lung02: a study of patritumab deruxtecan versus platinum-based chemotherapy in metastatic or locally advanced EGFRm NSCLC after failure of EGFR TKI therapy | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05338970"},{"key":"e_1_3_5_208_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8506"},{"key":"e_1_3_5_209_1","unstructured":"Patritumab deruxtecan biologics license application for patients with previously treated locally advanced or metastatic EGFR-mutated non-small cell lung cancer voluntarily withdrawn - Merck.com [Internet]. [cited 2026 Apr 12]. Available from: https:\/\/www.merck.com\/news\/patritumab-deruxtecan-biologics-license-application-for-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-voluntarily-withdrawn\/"},{"key":"e_1_3_5_210_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106318"},{"key":"e_1_3_5_211_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00159-1"},{"key":"e_1_3_5_212_1","unstructured":"Study details | NCT05865990 | HER3-DXd in breast cancer and NSCLC brain metastases and solid tumor leptomeningeal disease | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05865990"},{"key":"e_1_3_5_213_1","unstructured":"Study details | NCT05620914 | a window of opportunity study of patritumab deruxtecan in patients with brain metastases | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05620914"},{"key":"e_1_3_5_214_1","unstructured":"Study details | NCT04676477 | HER3-DXd (patritumab deruxtecan; U3-1402) in combination with osimertinib in subjects with locally advanced or metastatic EGFR-mutated non-small cell lung cancer | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04676477"},{"key":"e_1_3_5_215_1","unstructured":"Study details | NCT05880706 | a study of BL-B01D1 and BL-B01D1 in combination with osimertinib mesylate tablets in patients with locally advanced or metastatic non-small cell lung cancer | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05880706"},{"key":"e_1_3_5_216_1","unstructured":"Study details | NCT06093503 | study of intravenous telisotuzumab vedotin in combination osimertinib or standard of care chemotherapy to assess change in disease activity in adult participants with non-small cell lung cancer that has a mutation in the epidermal growth factor receptor gene and that overexpresses the c-met protein | ClinicalTrials.gov [Internet]. [cited 2026 Mar 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06093503"},{"key":"e_1_3_5_217_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00739"},{"key":"e_1_3_5_218_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.001"},{"key":"e_1_3_5_219_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1869"},{"key":"e_1_3_5_220_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-5736"},{"key":"e_1_3_5_221_1","unstructured":"Study details | NCT05948865 | a phase 1 study of CPO301 in adult patients with advanced or metastatic solid tumors | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05948865"},{"key":"e_1_3_5_222_1","unstructured":"Study details | NCT06210815 | a study of HLX42 in advanced\/metastatic solid tumors | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06210815"},{"key":"e_1_3_5_223_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3156"},{"key":"e_1_3_5_224_1","unstructured":"Study details | NCT05647122 | first in human study of AZD9592 in solid tumors | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05647122"},{"key":"e_1_3_5_225_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.01.002"},{"key":"e_1_3_5_226_1","unstructured":"Study details | NCT04335292 | osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge | ClinicalTrials.Gov [Internet]. [cited 2026 Jul 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04335292"},{"key":"e_1_3_5_227_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2580"},{"key":"e_1_3_5_228_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102824"},{"key":"e_1_3_5_229_1","unstructured":"Study details | NCT04862780 | (SYMPHONY) phase 1\/2 study targeting EGFR resistance mechanisms in NSCLC | ClinicalTrials.gov [Internet]. [cited 2026 Mar 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04862780"},{"key":"e_1_3_5_230_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9156"},{"key":"e_1_3_5_231_1","unstructured":"Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations. ASCO [Internet]. [cited 2026 Jul 1]. Available from: https:\/\/www.asco.org\/abstracts-presentations\/265943"},{"key":"e_1_3_5_232_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8622"},{"key":"e_1_3_5_233_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00818"},{"key":"e_1_3_5_234_1","unstructured":"Study details | NCT05261399 | savolitinib plus osimertinib versus platinum-based doublet chemotherapy in participants with non-small cell lung cancer who have progressed on osimertinib treatment | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05261399"},{"key":"e_1_3_5_235_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9110"},{"key":"e_1_3_5_236_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010006"},{"key":"e_1_3_5_237_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13521"},{"key":"e_1_3_5_238_1","unstructured":"Study details | NCT04545710 | osimertinib and abemaciclib in EGFR mutant non-small cell lung cancer after osimertinib resistance | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04545710"},{"key":"e_1_3_5_239_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11091460"},{"key":"e_1_3_5_240_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1238539"},{"key":"e_1_3_5_241_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002531"},{"key":"e_1_3_5_242_1","unstructured":"Study details | NCT02897765 | a personal cancer vaccine (NEO-PV-01) w\/ nivolumab for patients with melanoma lung cancer or bladder cancer | ClinicalTrials.gov [Internet]. [cited 2026 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02897765"},{"key":"e_1_3_5_243_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_3_5_244_1","unstructured":"Study details | NCT06050980 | phase I study of HSK40118 in NSCLC patients with EGFR mutation | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06050980"},{"key":"e_1_3_5_245_1","unstructured":"Study details | NCT06641609 | a phase I study of CFT8919 in patients with advanced NSCLC | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06641609"},{"key":"e_1_3_5_246_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0835"},{"key":"e_1_3_5_247_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01566"},{"key":"e_1_3_5_248_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0716"},{"key":"e_1_3_5_249_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30264-9"},{"key":"e_1_3_5_250_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3146"},{"key":"e_1_3_5_251_1","unstructured":"Study details | NCT05281406 | additional chemotherapy for EGFRm patients with the continued presence of plasma CtDNA EGFRm at week 3 after start of osimertinib 1st-line treatment (PACE-LUNG) | ClinicalTrials.gov [Internet]. [cited 2026 Mar 8]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05281406"},{"key":"e_1_3_5_252_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.07.008"},{"key":"e_1_3_5_253_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70861"},{"key":"e_1_3_5_254_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3929"},{"key":"e_1_3_5_255_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1527614"},{"key":"e_1_3_5_256_1","unstructured":"ISPOR - Cost-effectiveness of amivantamab plus lazertinib for first-line treatment of EGFR-mutated advanced non-small cell lung cancer: a U.S. payer perspective [Internet]. [cited 2026 Apr 5]. Available from: https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation-cti\/ispor-2026\/poster-session-5-3\/cost-effectiveness-of-amivantamab-plus-lazertinib-for-first-line-treatment-of-egfr-mutated-advanced-non-small-cell-lung-cancer-a-u-s-payer-perspective"},{"key":"e_1_3_5_257_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01001"},{"key":"e_1_3_5_258_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106320"},{"key":"e_1_3_5_259_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.12.009"},{"key":"e_1_3_5_260_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02276-9"},{"key":"e_1_3_5_261_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11867-6"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2702380","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2702380","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2702380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:10:53Z","timestamp":1785744653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2702380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":259,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,7,24]]}},"alternative-id":["10.1080\/14656566.2026.2702380"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2702380","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}